<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327663</url>
  </required_header>
  <id_info>
    <org_study_id>FTC-01</org_study_id>
    <nct_id>NCT02327663</nct_id>
  </id_info>
  <brief_title>Emtricitabine for Naive Chinese Chronic Hepatitis B Patients</brief_title>
  <official_title>Emtricitabine for Naive Chinese Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian-Pacific Alliance of Liver Disease, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Pharmaceutical Factory</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Family Planning Commission, P.R.China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asian-Pacific Alliance of Liver Disease, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates generic emtricitabine(FTC) in Chinese naive chronic hepatitis B
      patients. Patients were divided into 2 groups: HBeAg positive Chronic hepatitis B(CHB)group
      and HBeAg negative Chronic hepatitis B(CHB)group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Generic emtricitabine(FTC) has been approved for treatment of naive chronic hepatitis B(CHB)
      patients in China. Yet data are limited for this agent. The investigators design this trial
      to test the effect of FTC in Chinese CHB which including naive HBeAg positive and Negative
      CHB patients. Response guided therapy strategy is adopted for patients who can not achieve
      HBV DNA negativity at week 24 FTC treatment, which means FTC and adefovir are combined for
      these patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>virological response rate</measure>
    <time_frame>week 96</time_frame>
    <description>HBV DNA &lt; 500 copies/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV DNA decrease level</measure>
    <time_frame>week24, 48, 72 and 96</time_frame>
    <description>HBV DNA decrease compared with baseline（log10 copies/ml）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA negativity rate</measure>
    <time_frame>week 24, 48 and 72</time_frame>
    <description>HBV DNA &lt; 500 copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical response</measure>
    <time_frame>week 24,48,72 and 96</time_frame>
    <description>ALT normalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss</measure>
    <time_frame>week 24,48,72 and 96</time_frame>
    <description>HBeAg loss in HBeAg positive group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion</measure>
    <time_frame>week 24,48,72 and 96</time_frame>
    <description>HBeAg seroconversion in HBeAg positive group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg reversion</measure>
    <time_frame>week 24,48,72 and 96</time_frame>
    <description>HBeAg positive in Baseline HBeAg negativie group patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss</measure>
    <time_frame>week 24,48,72 and 96</time_frame>
    <description>HBsAg loss in both group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg seroconversion</measure>
    <time_frame>week 24,48,72 and 96</time_frame>
    <description>HBsAg loss and anti-HBs positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>week 24,48,72 and 96</time_frame>
    <description>type and rate of adverse events;type and rate of severe adverse event;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV genetic resistance to emtricitabine and adefovir</measure>
    <time_frame>week 24,48,72 and 96</time_frame>
    <description>HBV genetic resistance to emtricitabine and adefovir</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>HBeAg positive CHB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA &gt; 500 copies/ml, adefovir dipivoxil were combined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBeAg negativie CHB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA &gt; 500 copies/ml, adefovir dipivoxil were combined</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24</description>
    <arm_group_label>HBeAg positive CHB group</arm_group_label>
    <arm_group_label>HBeAg negativie CHB group</arm_group_label>
    <other_name>Brand name：Huierding</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HBsAg positive for more than 6 months

          -  HBeAg positive patients: HBV DNA ≥ 5log10 copies/ml

          -  HBeAg postive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver
             biopsy Knodell HAI ≥ 4

          -  HBeAg negative patients: HBV DNA ≥ 4log10 copies/ml

          -  HBeAg postive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver
             biopsy Knodell HAI ≥ 4

          -  nucleoside/nucleotide naive paitents

        Exclusion Criteria:

          -  Diagnosed HCC with AFP and ultrasound, CT or MRI

          -  Creatine ＞130μmol/L or Ccr &lt; 70mL/min

          -  Hemoglobin &lt;100g/L

          -  Neutrophils &lt;1.5E+9/L

          -  PLT&lt;80E+9/L

          -  Coinfected with HAV,HEV,HCV,HDV or HIV

          -  ANA ＞ 1:100

          -  Uncontrolled cardiovascluar diseases, kidney diseases,lung diseases, neurological
             diseases, digestive diseases,metabolic disorders, immune-compromised diseases or
             cancer

          -  Drug abuse or alcohal addiction

          -  Previous history of taking agents of lamivudine, adefovir, tenofovir entecavir or
             telbivudine

          -  Long-term use of immunosuppressor or immunomodulator 6 months before enrollment to
             this trial

          -  Underwent liver transplantation or liver transplantation in schedule

          -  Allergic to nucleoside or nucleotide analogues

          -  Preganency or in breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Cheng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asian Pacific Alliance of Liver Diseases, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Cheng, M.D.</last_name>
    <phone>+86 10 84322116</phone>
    <email>jun.cheng.ditan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Song Yang, M.D.</last_name>
    <phone>+86 15011210692</phone>
    <email>sduyangsong@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, Lee SS, Chan S, Shiffman ML, Washington MK, Rigney A, Anderson J, Mondou E, Snow A, Sorbel J, Guan R, Rousseau F; Emtricitabine FTCB-301 Study Group. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006 Jan 9;166(1):49-56.</citation>
    <PMID>16401810</PMID>
  </reference>
  <results_reference>
    <citation>Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother. 2002 Jun;46(6):1734-40.</citation>
    <PMID>12019083</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asian-Pacific Alliance of Liver Disease, Beijing</investigator_affiliation>
    <investigator_full_name>Jun Cheng</investigator_full_name>
    <investigator_title>chaireman of Asian-Pacific Alliance of Liver Diseas,Beijing</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B, chronic</keyword>
  <keyword>Emtricitabine</keyword>
  <keyword>Adefovir dipivixil</keyword>
  <keyword>HBeAg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

